To develop a prognostication tool for glioblastoma (GBM) patients based on clinical, radiological, and molecular factors to estimate individual survival probabilities for newly diagnosed patients.
Key Findings:
Younger age, better clinical status, tumor location, gross total resection, and MGMT promoter methylation are significant prognostic factors that influence survival outcomes.
No established prognostication system exists that weights these prognostic factors for personalized prognosis in GBM, highlighting a gap in current clinical practice.
Interpretation:
The study underscores the necessity for a personalized prognostication tool that integrates various factors influencing survival in GBM patients, potentially transforming clinical decision-making.
Limitations:
Retrospective design may introduce bias, limiting the generalizability of the findings.
Molecular marker data only available for patients diagnosed from 2016 to 2021, which may affect the comprehensiveness of the analysis.
Conclusion:
A personalized prognosis estimation tool for GBM patients could significantly enhance treatment decision-making and patient counseling, ultimately improving patient outcomes.
